Background
Withania somnifera (ashwagandha) is a foundational herb in Ayurvedic medicine, used historically as a rasayana (rejuvenator) and nervine tonic. Traditional preparations use dried root powder or decoctions to support vitality, stress resilience, and sexual health. KSM-66 is a proprietary extract developed by Ixoreal Biomed to concentrate root phytochemicals while preserving the full spectrum of root constituents, enabling standardized dosing for clinical research. Controlled trials examining standardized ashwagandha extracts for stress, cognition, and physical performance began appearing in the 2010s.
Evidence snapshot
Several randomized, placebo-controlled trials using KSM-66 report reductions in perceived stress and serum cortisol at doses around 300 mg twice daily (600 mg/day). Results are generally favorable, though sample sizes are modest and study duration is typically 8–12 weeks.
Evidence for exercise recovery and strength comes from a small number of trials showing modest improvements in muscle strength, size, and recovery markers in resistance-trained men taking ~600 mg/day. Findings are promising but not definitive across populations.
Some clinical trials using KSM-66 or other root extracts report improvements in sexual function and serum testosterone in men, and improvements in sleep and cognition in limited studies. Heterogeneity in formulations, endpoints, and blinding warrants caution in generalizing results.
Short-term trials (8–12 weeks) indicate KSM-66 is generally well tolerated. Long-term safety evidence beyond several months is limited; caution is advised during pregnancy and breastfeeding and when taken alongside certain medications (see Interactions).
Standardization and what 'KSM-66' means
KSM-66 is a trademarked, full-spectrum, root-only extract produced by Ixoreal Biomed. It is standardized to approximately 5% withanolides by HPLC per manufacturer specifications. The extraction process uses root-only starting material, distinguishing it from leaf-inclusive extracts such as Sensoril. Standardization to a defined withanolide percentage is intended to ensure batch-to-batch consistency in clinical and commercial products.
Bioavailability and formulation considerations
Withanolides are moderately lipophilic. Clinical trials have used oral capsules or tablets at 300–600 mg/day. Some formulations combine ashwagandha with black pepper extract (piperine) or dietary fats to support absorption, but head-to-head bioavailability data specifically for KSM-66 are limited. Taking with food improves tolerability and may support absorption of lipophilic constituents.
Populations studied and limitations
Most randomized controlled trials have enrolled healthy adults under stress or recreationally active men. Evidence in older adults, women, pregnant or breastfeeding individuals, children, and those with chronic medical conditions is limited or absent. Most trials are small (tens to low hundreds of participants) and run 8–12 weeks; long-term outcomes and rare adverse events are not well characterized.
Long-term safety and regulatory status
Short-term clinical trials (up to ~3 months) report good tolerability overall. In most jurisdictions, KSM-66 is sold as a dietary supplement and is not approved as a pharmaceutical. Given the absence of long-term safety data, clinicians commonly advise against use during pregnancy or breastfeeding and recommend monitoring if taken alongside thyroid medications or immunosuppressants.
Compound variations
KSM-66 (full-spectrum root extract, ~5% withanolides)
Root-only standardized extract used in most clinical trials; designed to preserve the full profile of root constituents.
Common use case
General stress reduction, exercise recovery, male sexual health (as studied in clinical populations).
Dosage note
Common clinical dosing: 300 mg twice daily (600 mg/day total).
Ashwagandha root powder
Traditional powdered root used in Ayurvedic formulas; much less concentrated in withanolides than standardized extracts.
Common use case
Traditional use as a tonic; users preferring whole-root preparations.
Dosage note
Traditional doses range approximately 1–6 g/day; do not equate directly to standardized extract doses.
Sensoril (leaf + root extract)
A different proprietary extract derived from both leaf and root; standardized to higher total withanolide content and may have different clinical effects and dosing requirements.
Common use case
Products targeting stress or cognitive endpoints where Sensoril has been specifically studied.
Dosage note
Follow product labeling; Sensoril dosing in trials generally differs from KSM-66 and is typically lower by weight.
Dosage and best practices
Dosage principles
- Common clinical dosing for KSM-66: 300 mg twice daily (600 mg/day total) — used in RCTs for stress, anxiety, and exercise outcomes.
- Some trials have used 300 mg once daily for mild outcomes; most controlled research uses the 600 mg/day dose.
- Traditional Ayurvedic root powder dosing ranges from approximately 1–6 g/day and is not directly comparable to standardized extract doses due to differences in withanolide concentration.
Best practices
- Take with food if you experience mild gastrointestinal upset; most trials administered KSM-66 with meals.
- Start at 300 mg/day and assess tolerance before moving to 600 mg/day when targeting stress or performance outcomes.
- Allow 6–12 weeks to assess effects on stress, sleep, or training adaptations; most trials measure primary outcomes at 8–12 weeks.
Literature and references
A prospective, randomized double-blind, placebo-controlled study of a high-concentration full-spectrum Ashwagandha root extract in reducing stress and anxiety in adults
Indian Journal of Psychological Medicine • 2012
Randomized trial (N=64) using 300 mg twice daily (600 mg/day) KSM-66 reported significant reductions in perceived stress and serum cortisol versus placebo over 60 days.
Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial
Journal of the International Society of Sports Nutrition • 2015
In resistance-trained men, 600 mg/day of KSM-66 root extract for 8 weeks improved muscle strength and recovery markers relative to placebo.
Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis
Human psychopharmacology • 2024
Systematic review and meta-analysis of randomized placebo-controlled trials of Withania somnifera in people with anxiety or insomnia, assessing Hamilton Anxiety Scale scores and sleep measures.
Common questions
How long until I might notice benefits?
Clinical trials generally assess primary outcomes at 8–12 weeks. Some participants report reduced stress or improved sleep within 2–4 weeks, but objective improvements in cortisol or strength measures are typically observed after 8 weeks of consistent use.
Is KSM-66 the same as other ashwagandha extracts like Sensoril?
No. KSM-66 is a root-only, full-spectrum extract standardized to withanolides from root tissue. Sensoril is a different proprietary extract that includes both leaf and root material and is standardized to different markers; physiological effects and appropriate dosing may differ between the two.
Can I take KSM-66 with my antidepressant or sleep medication?
Ashwagandha has sedative properties that could interact pharmacodynamically with sedatives or anxiolytics. Direct evidence of harmful drug interactions is limited, but discuss combination use with your clinician before starting.
Is it safe during pregnancy?
Ashwagandha is generally considered contraindicated during pregnancy and breastfeeding due to insufficient safety data and traditional cautions. Consult your healthcare provider before use.